D-0295-2025 Class II Ongoing

Recalled by QuVa Pharma, Inc. — Sugar Land, TX

FDA drug recall D-0295-2025 was initiated by QuVa Pharma, Inc. on Mar 6, 2025 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is ongoing.

Recall details

Product Type
Drugs
Report Date
Apr 2, 2025
Initiation Date
Mar 6, 2025
Voluntary/Mandated
Voluntary: Firm initiated

Product description

fentaNYL Citrate PF 200 mcg/100 mL (2 mcg/ml) /0.1% Bupivacaine HCl 100 mg/100 mL (1 mg/mL), 100 ml in NS Yellow CADD FSFF, Injection for Epidural Use (Not intended For IV Use), Compounded, For Institutional or Office Use Only, QuVa Pharma, 1075 West Park One Drive, Suite 100, Sugar Land, Tx 77478. NDC: 70092-1255-75

Reason for recall

Lack of Assurance of Sterility

Distribution pattern

U.S. Nationwide

Code information

Lots: 10140259, 10140539, 10140687, 10140688; Exp 04/24/2025

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0295-2025
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0295-2025. Report a data issue: hello@regdatalab.com.